The Pilot Longitudinal Study in Alzheimer’s Disease of Central Markers of Microglial Activation (PADMMA) combines brain imaging with key biomarkers to identify the role of inflammation in neurodegenerative
The peptides are aimed to treat severe medical conditions such as Cushing’s disease. Under the research collaboration, Ipsen’s expertise in design and development of therapeutic peptides targeting specific
A total of 117 patients were enrolled at over 20 sites in the US and Canada for the company’s PUNCH CD 2 multi-center, randomized, double-blind, placebo-controlled trial to
Under the licence and asset purchase agreement, Mundipharma will have rights associated to research, development, marketing, sales, and intellectual property rights and access to existing inventory of Zevalin
Avelumab, also known as MSB0010718C, inhibits PD-L1 interactions to potentially allow the activation of T-cells and the adaptive immune system. It is believed to engage the innate immune
Kalydeco has also been approved to use in CF patients at least 18 years old and more who have an R117H mutation. Vertex had earlier secured approval to
Helsinn Healthcare together with Roche Palo Alto filed an infringement lawsuit against Teva Pharmaceuticals USA and Teva Pharmaceutical Industries (collectively Teva) in the US. The US District Court
The Phase I/IIa trial, which is anticipated to start in the first half of 2016, will be funded and carried out by the NCI on about 55 patients.
The extension will run until November 2019 with an option to add another year. Summit will retain the exclusive rights to any intellectual property resulting from the alliance.
Roche’s option stems from a pre-existing deal with Novartis. Ophthotech’s agreement with Novartis, which was signed in May last year, remains in effect. Ophthotech retains exclusive rights to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.